Literature DB >> 15583875

[Cardiovascular risk assessment for informed decision making. Validity of prediction tools].

Matthias Lenz1, Ingrid Mühlhauser.   

Abstract

BACKGROUND AND
PURPOSE: Patient involvement in health care decisions is increasingly requested. The authors investigated whether currently available assessment tools for prediction of cardiovascular risk can be used for individual risk prediction as a basis of informed decision making.
METHODS: The authors searched for risk assessment tools and respective validation studies in Medline (until August 16, 2004) and the Cochrane Library (issue 2/2004). The following criteria were used for evaluation of prognostic studies: (1) discrimination between risk groups; (2) predictive values; (3) prognostic agreement; (4) transferability across populations.
RESULTS: A total of twelve assessment tools were identified. The Framingham function, Sheffield Tables, Canadian Tables, Framingham Categorial, New Zealand, Joint British, and European Charts (1994 and 1998) are based on the Framingham Study; PROCAM Risk Score, UKPDS Risk Engine, and SCORE Risk Charts use different source data. Framingham-based instruments overestimate cardiovascular risk of Central-European populations by at least 30%, with substantial regional variation even within a country (between 30% and 100%, British Regional Heart Study). Therefore, prior to application the assessment tools would need recalibration using regional data of cardiovascular mortality and adjustment for social class differences. Published sensitivity, specificity, and C-statistics for external validation (area under the curve [AUC] approximately 0.6) are clearly inferior to internal validation (AUC approximately 0.8). Agreement between instruments beyond chance is moderate (kappa approximately 0.5). No studies on external validation could be identified for the new European SCORE Risk Charts and UKPDS Risk Engine.
CONCLUSION: Validation of currently available assessment tools for cardiovascular risk prediction is inadequate. Uncritical use may lead to substantial under- or overestimation of individual cardiovascular risk and inappropriate treatment decisions.

Entities:  

Mesh:

Year:  2004        PMID: 15583875     DOI: 10.1007/s00063-004-1097-3

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  8 in total

Review 1.  Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review.

Authors:  P Brindle; A Beswick; T Fahey; S Ebrahim
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

2.  Can non-physician health-care workers assess and manage cardiovascular risk in primary care?

Authors:  Dele O Abegunde; Bakuti Shengelia; Anne Luyten; Alexandra Cameron; Francesca Celletti; Sania Nishtar; Vasu Pandurangi; Shanthi Mendis
Journal:  Bull World Health Organ       Date:  2007-06       Impact factor: 9.408

3.  The Framingham Heart Study's impact on global risk assessment.

Authors:  Asaf Bitton; Thomas A Gaziano
Journal:  Prog Cardiovasc Dis       Date:  2010 Jul-Aug       Impact factor: 8.194

4.  [Impact of both cardiac-CT and cardiac-MR on the assessment of coronary risk].

Authors:  S Silber; B M Richartz
Journal:  Z Kardiol       Date:  2005

5.  An evidence-based shared decision making programme on the prevention of myocardial infarction in type 2 diabetes: protocol of a randomised-controlled trial.

Authors:  Susanne Buhse; Tabitha Heller; Jürgen Kasper; Ingrid Mühlhauser; Ulrich Alfons Müller; Thomas Lehmann; Matthias Lenz
Journal:  BMC Fam Pract       Date:  2013-10-19       Impact factor: 2.497

6.  Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to date.

Authors:  Thrasivoulos Tzellos; Athanassios Kyrgidis; Anastasia Trigoni; Christos C Zouboulis
Journal:  Dermatoendocrinol       Date:  2012-07-01

7.  Prospective health care: the second transformation of medicine.

Authors:  Ralph Snyderman; Jason Langheier
Journal:  Genome Biol       Date:  2006-02-27       Impact factor: 13.583

8.  Informed shared decision-making programme on the prevention of myocardial infarction in type 2 diabetes: a randomised controlled trial.

Authors:  Susanne Buhse; Ingrid Mühlhauser; Tabitha Heller; Nadine Kuniss; Ulrich Alfons Müller; Jürgen Kasper; Thomas Lehmann; Matthias Lenz
Journal:  BMJ Open       Date:  2015-11-13       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.